- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05091385
Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
The Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Treated in Poland. The Real-life Observational Study
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg SC every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Target population to be recruited has been set at 130 subjects from at least 6 asthma centers throughout the country. Data on dempgraphics and asthma status will be collected using questionnaires at 3 time-points: pre-MEPO, after 24 weeks of MEPO and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks). Primary endpoints will include:
- Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment.
- Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study is aimed at evaluation of the efficacy of mepolizumab 100 mg SC every 4 weeks in patients with severe eosinophilic asthma who have been treated for at least 12 months in several Polish allergy/asthma centres under the same protocol. Retrospective multicentre observational study will involve 130 patients with severe eosinophilic asthma ( SEA ) who have been treated in six Severe Asthma Treatment Centres ( SATCs) in Poland. In each SATC all data available in the program questionnaires will be transferred to the Study Data Sheet (questionnaire), and will be send to the study coordinator within 5 months from the study beginning The start-up meeting including partners from all centres involved will be organized to discuss the study protocol and to unify data collection The evaluation parameters (exacerbations rate, OCS dose) will be analysed at least at three time points: pre-MEPO, after 24 weeks of MEPO and after 1 year of MEPO administration (some of the outcomes will be observed every 4 weeks, for the details see 'study endpoints' section).
In addition the following parameters which are available in patients' records will be analysed:
- ACQ-5 score (measured at qualification for the treatment and every 4 weeks thereafter)
- AQLQ score (measured at qualification for the treatment and every 4 weeks thereafter)
- Pre-bronchodilator FEV1 (measured at qualification for the treatment and every 4 weeks thereafter)
Research activities will include:
- collecting raw data from the clinical centres (paper version) and constructing a raw dataset (digital version),
- data cleaning, computation of variables,
- statistical analysis typical for pre-post study design (the statistical analysis will be outsourced to the specialized private institute).
Clinical improvements observed at 24 weeks and at 52 weeks of treatment with Mepolizumab will be referred to the following characteristics of patients at baseline:
- demographics,
- presence of comorbidities including the atopic status,
- concomitant pharmacotherapy,
- clinical status,
- eosinophilia. We will control for mepolizumab use regarding dose, treatment duration and dosing frequency as well as for the safety profile based on the AEs reporting in the medical documentation.
Data Source / Data Collection Patients recruited to the study had been treated with mepolizumab between December 2017 and December 2019.All the data planned to be used in the proposed study were systematically collected in the form of the clinical documentation (paper version) and will be transferred in the study centres into the study.
Data Sheets. Collaborating Researchers (Severe Asthma Centres' Leaders) will provide the data input into the dedicated online questionnaire.
Study Population 130 Patients who were treated with mepolizumab in six severe-asthma clinics in Poland between December 2017 and December 2019 . In the drug program in Poland it was mandatory to conduct the control examinations at the 24th and 52nd week of the treatment . In the proposed study we will use this information to evaluate study endpoints. Only patients who have been treated for at least 52 weeks are included into the study
Variables concerning the primary endpoints
- Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment.
- Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment)
Variables concerning the secondary endpoints:
- ACQ-5 score (measured at qualification for the treatment and every 4 weeks thereafter)
- AQLQ score (measured at qualification for the treatment and every 4 weeks thereafter)
- Pre-bronchodilator FEV1 (measured at qualification for the treatment and every 4 weeks thereafter)
- Blood eosinophil counts (measured at qualification for the treatment and at the 24th and 52nd week of the treatment)
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Marcin Kurowski, MD, PhD
- Numero di telefono: +48601365911
- Email: marcin.kurowski@umed.lodz.pl
Backup dei contatti dello studio
- Nome: Aleksandra Wardzyńska, MD, PhD
- Numero di telefono: +48693652775
- Email: aleksandra.wardzynska@umed.lodz.pl
Luoghi di studio
-
-
-
Lodz, Polonia, 92-213
- Medical University of Lodz, Dept. of Immunology and Allergy
-
Contatto:
- Marcin Kurowski, MD, PhD
- Numero di telefono: +48601365911
- Email: marcin.kurowski@umed.lodz.pl
-
Contatto:
- Aleksandra Wardzyńska, MD, PhD
- Numero di telefono: +48693652775
- Email: aleksandra.wardzynska@umed.lodz.pl
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
* The availability of the complete data
- Duration of treatment with mepolizumab: ≥ 52 weeks
- Satisfying the Polish drug programme inclusion criteria:
- Age >18
Before treatment with mepolizumab (BSAT inclusion criteria):
- High doses of ICS + one other controlling medication (i.e. LABA)
- ≥2 exacerbations in the previous year
- ≥350 eosinophil cells/μl in the blood at the time of qualifying, or in the previous year
- Pre-bronchodilator FEV1 < 80%
Exclusion Criteria:
* Duration of treatment with mepolizumab < 52 weeks
• Lack of complete data
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
Severe asthma patients treated with mepolizumab
Patients having received mepolizumab 100 mg SC every 4 weeks for at least 12 months in six severe-asthma clinics in Poland between December 2017 and December 2019
|
Mepolizumab administered within the frame of a severe asthma treatment program financed by National Health Fund in Poland for patients fulfilling specific criteria of asthma severity.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Asthma exacerbations measured at qualification for the treatment (in the period of previous 52 weeks) and at the 24th and 52nd week of the treatment
Lasso di tempo: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet.
Asthma exacerbations, defined according to the Polish drug programme, is the worsening in asthma requiring (1) use of systemic corticosteroids or (2) increase in dose of OCS for more than 3 days in case of patients who are chronically treated with OCS.
|
5 months from the study beginning
|
Oral Corticosteroids use dose (documented at qualification for the treatment and at the 24th and 52nd week of the treatment)
Lasso di tempo: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
ACQ-5 score (measured at qualification for the treatment and every 4 weeks thereafter)
Lasso di tempo: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
AQLQ score (measured at qualification for the treatment and every 4 weeks thereafter)
Lasso di tempo: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
Pre-bronchodilator FEV1 (measured at qualification for the treatment and every 4 weeks thereafter)
Lasso di tempo: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
Blood eosinophil counts (measured at qualification for the treatment and at the 24th and 52nd week of the treatment)
Lasso di tempo: 5 months from the study beginning
|
Data as transferred from the treatment program questionnaires to the Study Data Sheet
|
5 months from the study beginning
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Marcin Kurowski, MD, PhD, Medical University of Lodz
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie delle vie respiratorie
- Malattie del sistema immunitario
- Malattie polmonari
- Ipersensibilità, immediata
- Malattie ematologiche
- Malattie bronchiali
- Malattie polmonari, ostruttive
- Ipersensibilità respiratoria
- Ipersensibilità
- Disturbi dei leucociti
- Eosinofilia
- Sindrome ipereosinofila
- Asma
- Eosinofilia polmonare
Altri numeri di identificazione dello studio
- 10867
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .